Rhelion Life Sciences Corp (RHEL.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 228 | 231 | 208 | 420 | 171 |
| Income taxes - deferred | -16 | -15 | -15 | -38 | -16 |
| Accounts receivable | 1,524 | -712 | -33 | -9 | -93 |
| Other Working Capital | 1,276 | -889 | 454 | 250 | 81 |
| Other Operating Activity | -2,414 | 162 | -923 | -1,385 | -914 |
| Operating Cash Flow | $598 | $-1,222 | $-310 | $-761 | $-771 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -33 | -9 | -444 | -214 | -79 |
| Sale Of Investment | N/A | N/A | N/A | 11 | 0 |
| Investing Cash Flow | $-33 | $-9 | $-444 | $-204 | $-79 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 0 | 0 | 559 | N/A | N/A |
| Debt Repayment | -63 | -68 | -56 | -53 | -56 |
| Common Stock Repurchased | 0 | N/A | N/A | -11 | -62 |
| Financing Cash Flow | $-63 | $-68 | $503 | $-65 | $-118 |
| Exchange Rate Effect | 2 | -43 | 6 | -17 | 23 |
| Beginning Cash Position | 12,786 | 14,128 | 14,372 | 15,419 | 16,364 |
| End Cash Position | 13,291 | 12,786 | 14,128 | 14,372 | 15,419 |
| Net Cash Flow | $502 | $-1,299 | $-251 | $-1,030 | $-968 |
| Free Cash Flow | |||||
| Operating Cash Flow | 598 | -1,222 | -310 | -761 | -771 |
| Capital Expenditure | -39 | -9 | -444 | -227 | -79 |
| Free Cash Flow | 560 | -1,231 | -754 | -989 | -850 |